Swedish biotech Anocca treats first pancreatic cancer patient; investors seek AstraZeneca 2.0

Anocca, a Swedish biotech backed by major investors, has administered its novel cancer therapy to the first Swedish pancreatic cancer patient. The company now needs capital to scale up, with questions over whether the technology will remain in Sweden. This marks a clinical milestone but commercial viability and domestic retention remain uncertain.